Gyn-Onc Funding Acknowledgements

Since the opening of the Gynecologic Oncology Clinic of the JGH in 2003, the following philanthropists and organizations have been funding various research projects carried out by the team. Thank you for your generous and continued support which enables us to trek in the journey of improving care for gynecologic cancers.

Funding sources are listed alphabetically with the respective funded research papers or book chapters in chronological order.

We would also like to thank those anonymous donors who have supported us to conduct research on robot-assisted surgery. For the papers on this topic, please click here.

Funding sourceTitle of paper
American Physicians Fellowship for Medicine in Israel

1. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study (2015)
2. Outcome and Quality of Life in a Prospective Cohort of the First 100 Robotic Surgeries for Endometrial Cancer, With Focus on Elderly Patients (2010)
3. Robotic-assisted minimally invasive surgery and ovarian cancer (2010)

Astra Zeneca Inc1. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer (2017)
Canadian Foundation for Women's Health1. The Fallopian Tube (2009)
2. Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma (2009)
3. Post-operative ascites following lymphadenectomy for early stage endometrial cancer (2008)
4. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer (2008)
5. Sarcoma post-embolization for presumed uterine fibroids (2007)
6. Doxorubicin levels in the serum and ascites of patients with ovarian cancer (2006)
CIHR1. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors (2015)
2. Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization (2011)
Dr Hoffman FundOutcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery (2012)
Fonds de recherche en santé du Québec1. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines (2016)
2. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors (2015)
3. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors (2015)
4. Combination of Serum Biomarkers to Di erentiate Malignant From Benign Ovarian Tumours (2012)
5. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer (2008)
6. Sarcoma post-embolization for presumed uterine fibroids (2007)
7. Doxorubicin levels in the serum and ascites of patients with ovarian cancer (2006)
8. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer (2005)
Francine Grzywacz Memorial FundOutside the operating room: How a robotics program changed resource utilization on the inpatient Ward (2017)
Friends for Life Foundation1. Molecular Basis of Gynecologic Cancers (2011)
2. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides (2011)
3. Technical modifications in the robotic-assisted surgical approach for gynaecologic operations (2010)
4. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide (2009)
5. Book chapter: Molecular Basics of Gynecologic Cancers (2006)
Garber Fund1. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)
2. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin (2017)
3. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)
Gloria Shapiro Foundation1. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)
2. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin (2017)
3. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer (2017)
4. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer (2017)
5. Outside the operating room: How a robotics program changed resource utilization on the inpatient Ward (2017)
6. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer (2017)
7. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)

Full List of Titles
Greenbaum Fund1. Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery (2012)
2. Outcome and Quality of Life in a Prospective Cohort of the First 100 Robotic Surgeries for Endometrial Cancer, With Focus on Elderly Patients (2010)
3. Technical modifications in the robotic-assisted surgical approach for gynaecologic operations (2010)
Greenberg Fund1. Anti-diabetic doses of metformin decrease proliferation markers in 2 tumors of patients with endometrial cancer (2014)
2. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides (2011)
Intuitive SurgicalOutside the operating room: How a robotics program changed resource utilization on the inpatient Ward (2017)
Israel Cancer Association1. Molecular Basis of Gynecologic Cancers: What Should We Know? (2016)
2. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study (2015)
3. Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery (2012)
4. Molecular Basis of Gynecologic Cancers (2011)
5. Robotic-assisted minimally invasive surgery and ovarian cancer (2010)
6. Outcome and Quality of Life in a Prospective Cohort of the First 100 Robotic Surgeries for Endometrial Cancer, With Focus on Elderly Patients (2010)
7. Papillary serous carcinoma in situ in ovarian endometriosis in an MSH2 mutation carrier (2009)
Israel Cancer Research Fund1. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors (2017)
2. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)
3. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin (2017)
4. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer (2017)
5. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer (2017)
6. Outside the operating room: How a robotics program changed resource utilization on the inpatient Ward (2017)
7. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer (2017)
8. Unexpected locations of sentinel lymph nodes in endometrial cancer(2017)

Full List of Titles
JGH Foundation1. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)
2. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin (2017)
3. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer (2017)
4. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)
Levy Family Fund1. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors (2017)
2. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin (2017)
3. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer (2017)
4. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines (2016)
5. Minimizing pain medication use and its associated costs following robotic surgery (2016)
6. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors (2015)
7. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors (2015)
8. Health-Related Quality of Life Following Robotic Surgery: A Pilot Study (2015)

Full List of Titles
Montreal Center for Experimental Therapeutics in Cancer1. HPV-related vulvar intraepithelial neoplasia: Outcome 3 of different management modalities (2007)
2. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer (2005)
NCICAnti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization (2011)
Norych Career Scientist Award1. Molecular Basis of Gynecologic Cancers: What Should We Know? (2016)
2. Molecular Basis of Gynecologic Cancers (2011)
3. Robotic radical hysterectomy: comparison of outcomes and cost (2010)
4. Outcome and Quality of Life in a Prospective Cohort of the First 100 Robotic Surgeries for Endometrial Cancer, With Focus on Elderly Patients (2010)
5. Technical modifications in the robotic-assisted surgical approach for gynaecologic operations (2010)
6. The Fallopian Tube (2009)
7. Post-operative ascites following lymphadenectomy for early stage endometrial cancer (2008)
8. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer (2008)

Full List of Titles
Nuovo Soldati Foundation for Cancer Research1. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors (2017)
2. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines (2016)
3. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors (2015)
Project EndoHealth-Related Quality of Life Following Robotic Surgery: A Pilot Study (2014)
Quebec Breast Cancer FoundationChemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors (2015)
Quebec Network for Research AgingProspective Quality of Life Outcomes Following Robotic Surgery in Gynecologic Oncology
Reseau de recherche sur le cancer1. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines (2016)
2. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors (2015)
3. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors (2015)
4. Combination o Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours (2012)
Ride to Conquer Cancer1. Benefits of robotic surgery for elderly patients with endometrial carcinoma (2013)
2. Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: A prospective study (2012)
Schouella Distinguished Scientist Award1. Molecular Basis of Gynecologic Cancers: What Should We Know? (2016)
2. Molecular Basis of Gynecologic Cancers (2011)
3. Robotic radical hysterectomy: comparison of outcomes and cost (2010)
4. Outcome and Quality of Life in a Prospective Cohort of the First 100 Robotic Surgeries for Endometrial Cancer, With Focus on Elderly Patients (2010)
5. Technical modifications in the robotic-assisted surgical approach for gynaecologic operations(2010)
6. The Fallopian Tube (2009)
7. Post-operative ascites following lymphadenectomy for early stage endometrial cancer (2008)
8. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer(2008)

Full List of Titles
Susan and Jonathan Wener Fund1. Unexpected locations of sentinel lymph nodes in endometrial cancer (2017)
2. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer (2017)
Turqwise Foundation1. Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery (2012)
2. Molecular Basis of Gynecologic Cancers (2011)
3. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides (2011)
4. Technical modifications in the robotic-assisted surgical approach for gynaecologic operations (2010)
5. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide (2009)
6. Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma(2009)
7. Book Chapter: Molecular Basics of Gynecologic Cancers(2006)
Visman Fund of Tel Aviv University1. Molecular Basis of Gynecologic Cancers: What Should We Know? (2016)
2. Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery (2012)
3. Molecular Basis of Gynecologic Cancers (2011)
4. Robotic-assisted minimally invasive surgery and ovarian cancer (2010)
5. Papillary serous carcinoma in situ in ovarian endometriosis in an MSH2 mutation carrier (2009)
6. Book chapter: Molecular Basics of Gynecologic Cancers (2006)
Weekend to End Women's Cancers

1. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors (2017)
2. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer (2017)
3. Outside the operating room: How a robotics program changed resource utilization on the inpatient Ward (2017)
4. Benefits of Minimal Access Surgery in Elderly Patients with Pelvic Cancer (2016)
5. Molecular Basis of Gynecologic Cancers: What Should We Know? (2016)
6. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines (2016)

Full List of Titles

Page last updated on 

We always seek feedback to make our site better.